ClinicalTrials.gov
ClinicalTrials.gov Menu

Progesterone and Second Trimester Bleeding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01269450
Recruitment Status : Terminated (Slow recruitment)
First Posted : January 4, 2011
Last Update Posted : January 23, 2018
Sponsor:
Information provided by (Responsible Party):
Raed Salim, HaEmek Medical Center, Israel

Study Description
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Working hypothesis and aims:

To investigate whether progesterone treatment affects the incidence of preterm labor compared to placebo, among women with 2nd trimester bleeding.

The participants will be allocated through randomization to a study or control group. Women in the study group will receive micronized progesterone 200 mg (Utrogestan, company) with an intra-vaginal tablet once daily while the control group will receive placebo. Both women and medical staff will be blinded to group allocation. Treatment will commence on the day of inclusion to the study, but not before 16 weeks and will continue until 36 weeks gestation. Data will be collected after the conclusion of pregnancy regarding the maternal and neonatal outcome.


Condition or disease Intervention/treatment Phase
Antepartum Bleeding Preterm Birth Drug: micronized progesterone 200 mg (Utrogestan) Drug: placebo Not Applicable

Study Design
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Impact of Progesterone on the Risk of Preterm Birth Among Women With Second Trimester Bleeding. A Double Blind Placebo Controlled Trial
Study Start Date : December 2010
Actual Primary Completion Date : January 2017
Actual Study Completion Date : July 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding
U.S. FDA Resources

Arms and Interventions
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Utrogestan Drug: micronized progesterone 200 mg (Utrogestan)
micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
Placebo Comparator: placebo Drug: placebo
placebo 200mg vaginal tablets


Outcome Measures
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of spontaneous preterm birth - before 37 weeks. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Maternal and fetal outcomes [ Time Frame: 3 years ]

Eligibility Criteria
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Viable pregnancy
  • Gestational age between 13 to 26 weeks
  • Vaginal bleeding from uterine origin
  • Singleton pregnancy
  • Normal clotting tests
  • Hemodynamically stable woman

Exclusion Criteria:

  • Water leak
  • Signs of preterm labor
  • Fetal malformations incompatible with life
  • Uterine malformations and other maternal conditions, i.e. liver disease, breast cancer, active thromboembolic state
  • Past preterm birth
Contacts and Locations
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01269450


Locations
Israel
Emek medical center
Afula, Israel, 18101
dEP ob/gyn, Hillel Yaffe Medical Center.
Hadera, Israel
Dep. OB/GYN, The Nazareth Hospital, E.M.M.S
Nazareth, Israel
Sponsors and Collaborators
HaEmek Medical Center, Israel
Investigators
Principal Investigator: RAED SALIM, MD HaEmek medical center affiliated to the Rappaport faculty of medicine, Technion, Haifa, Israel
More Information
Go to 
Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Additional Information:
Dep OB/GY, Emek Medical Center  This link exits the ClinicalTrials.gov site

Responsible Party: Raed Salim, Dr., HaEmek Medical Center, Israel
ClinicalTrials.gov Identifier: NCT01269450     History of Changes
Other Study ID Numbers: 0023-08-EMC
First Posted: January 4, 2011    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018

Keywords provided by Raed Salim, HaEmek Medical Center, Israel:
second trimester vaginal bleeding
late abortion
preterm birth
progesterone

Additional relevant MeSH terms:
Premature Birth
Hemorrhage
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Pathologic Processes
 Progesterone
Progestins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs